Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 77 King St. West, Suite 2905 TORONTO ON M5K 1H1 |
Tel: | N/A |
Website: | https://pharmadrug.ca |
IR: | See website |
Key People | ||
N/A |
Business Overview |
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company's subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. |
Financial Overview |
For the three months ended 31 March 2024, Pharmadrug Inc revenues was not reported. Net loss increased from C$179K to C$497K. Higher net loss reflects Business development increase from C$2K to C$290K (expense), Fair value change in investments decrease from C$159K (income) to C$0K, Research expense increase from C$13K to C$65K (expense). Basic Earnings per Share excluding Extraordinary Items totaled to -C$0.01. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $3.96M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$1.63M as of Mar 31, 2024 |
Net annual income (TTM): | -$13.52M as of Mar 31, 2024 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | $1.14M as of Mar 31, 2024 |
Shares outstanding: | 104,691,210 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |